PMID- 26961327
OWN - NLM
STAT- MEDLINE
DCOM- 20170124
LR  - 20211203
IS  - 1881-7831 (Print)
IS  - 1881-7831 (Linking)
VI  - 10
IP  - 2
DP  - 2016
TI  - Tenascin C affects mineralization of SaOS2 osteoblast-like cells through matrix 
      vesicles.
PG  - 82-7
LID - 10.5582/ddt.2016.01009 [doi]
AB  - Tenascin C (TNC) is an extracellular matrix glycoprotein involved in osteogenesis 
      and bone mineralization. In a previous study, we identified TNC protein located 
      in the matrix vesicles (MVs) of osteoblasts. MVs are determinant in the 
      mineralization formation. Therefore, we hypothesize whether TNC can modulate 
      osteoblast mineralization via MVs. In this study, we demonstrated that the 
      expression level of TNC was increased with osteoblast differentiation of 
      osteoblast-like SaOS2 cells, and down-regulation of TNC expression by siRNA could 
      significantly inhibit SaOS2 differentiation toward osteoblasts and mineralization 
      as evidenced by decreases in ALP activity, mineralized nodule formation, calcium 
      deposition, and down-regulation of osteogenic marker genes ALP, and COL1A1. 
      Furthermore, we validated that TNC located in the MVs of mineralized SaOS2 cells, 
      and that down-regulation of TNC could decrease MVs mineralization ability in 
      vitro, and the decrease of MVs mineralization ability was not associated with 
      annexins. In conclusion, in this study, we extended the role of TNC during 
      osteogenesis previous progresses, and that supported TNC as an important 
      functional MVs component in modulating osteoblast mineralization.
FAU - Li, Chengzhi
AU  - Li C
AD  - School of Medicine and Life Sciences, University of Jinan-Shandong Academy of 
      Medical Science.
FAU - Cui, Yazhou
AU  - Cui Y
FAU - Luan, Jing
AU  - Luan J
FAU - Zhou, Xiaoyan
AU  - Zhou X
FAU - Li, Haiying
AU  - Li H
FAU - Wang, Huaxin
AU  - Wang H
FAU - Shi, Liang
AU  - Shi L
FAU - Han, Jinxiang
AU  - Han J
LA  - eng
PT  - Journal Article
DEP - 20160222
PL  - Japan
TA  - Drug Discov Ther
JT  - Drug discoveries & therapeutics
JID - 101493809
RN  - 0 (Collagen Type I)
RN  - 0 (Collagen Type I, alpha 1 Chain)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tenascin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
SB  - IM
MH  - Alkaline Phosphatase/metabolism
MH  - Bone Matrix/*drug effects
MH  - Calcification, Physiologic/*genetics
MH  - Cell Differentiation/genetics
MH  - Cell Line, Tumor
MH  - Collagen Type I/biosynthesis/genetics
MH  - Collagen Type I, alpha 1 Chain
MH  - Down-Regulation
MH  - Extracellular Matrix/drug effects
MH  - Humans
MH  - Osteoblasts/*metabolism
MH  - Osteogenesis/genetics
MH  - RNA, Small Interfering/pharmacology
MH  - Tenascin/*biosynthesis/genetics
EDAT- 2016/03/11 06:00
MHDA- 2017/01/25 06:00
CRDT- 2016/03/11 06:00
PHST- 2016/03/11 06:00 [entrez]
PHST- 2016/03/11 06:00 [pubmed]
PHST- 2017/01/25 06:00 [medline]
AID - 10.5582/ddt.2016.01009 [doi]
PST - ppublish
SO  - Drug Discov Ther. 2016;10(2):82-7. doi: 10.5582/ddt.2016.01009. Epub 2016 Feb 22.